News related to Abilify (Aripiprazole) and/or conditions it is approved for
Immune System Activated In Schizophrenia
Source: Immune System / Vaccines News From Medical News Today [2009.11.19]
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system. The causes of schizophrenia are largely unknown, and this hinders the development of effective treatments.
Major Schizophrenia Study Finds Striking Similarities Across 37 Countries In Six Regions
Source: Mental Health News From Medical News Today [2009.11.16]
An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.
World's Leading Experts In Schizophrenia To Meet At 26th Annual Pittsburgh Schizophrenia Conference Nov. 13
Source: Schizophrenia News From Medical News Today [2009.11.08]
Internationally renowned experts in schizophrenia and other psychotic disorders, researchers and clinicians, patients and their families and friends will gather in Pittsburgh to discuss the latest in research and clinical advances at the 26th Annual Pittsburgh Schizophrenia Conference to be held Friday, Nov. 13, at the Sheraton Station Square, Pittsburgh.
Schizophrenia
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2009.10.30]
Title: Schizophrenia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 10/30/2009
Forest Laboratories, Inc. And Gedeon Richter Announce Positive Results From A Phase IIb Study Of Cariprazine For The Treatment Of Schizophrenia
Source: Schizophrenia News From Medical News Today [2009.10.29]
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.
New "Schizophrenia Gene" Prompts Researchers To Test Potential Drug Target
Source: Autism News From Medical News Today [2009.10.27]
Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism. The rescue, described as "surprisingly complete" by the researchers, was accomplished with rapamycin, a drug known to act on a protein called mTOR whose role involves the production of other proteins.
Onset Of Schizophrenia Triggered By Faulty 'Wiring' In The Brain
Source: Schizophrenia News From Medical News Today [2009.10.27]
A new study by researchers at the Institute of Psychiatry (IoP), King's College London has discovered abnormalities in the white matter of the brain that seem to be critical for the timing of schizophrenia. The study, led by Professor Phillip McGuire and Dr Sophia Frangou, has been published in this month's edition of the British Journal of Psychiatry. The white matter of the brain consists of nerve fibres that connect parts of the brain and help regulate behaviour.
Rare Mutation Linked To Autism Now Also Linked To Schizophrenia Risk
Source: Autism News From Medical News Today [2009.10.26]
An international team of researchers led by geneticist Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL), has identified a mutation on human chromosome 16 that substantially increases risk for schizophrenia. The mutation in question is what scientists call a copy number variant (CNV). CNVs are areas of the genome where the number of copies of genes differs between individuals. The CNV is located in a region referred to by scientists as 16p11.2.
Minimal Relationship Between Cannabis And Schizophrenia Or Psychosis Suggested By New UK Study
Source: Schizophrenia News From Medical News Today [2009.10.24]
Last year the UK government reclassified cannabis from a class C to a class B drug, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia in young people. But the evidence for the relationship between cannabis and schizophrenia or psychosis remains controversial. A new study has determined that it may be necessary to stop thousands of cannabis users in order to prevent a single case of schizophrenia.
$2.1 Million Grant Awarded For Genetic Study Of Schizophrenia To US And Hebrew University Researchers
Source: Schizophrenia News From Medical News Today [2009.10.23]
The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia.. The team, which also includes Drs. Anil Malhotra and Peter Gregersen of the Feinstein Institute and Dr.
Epilepsy Treatment Is A Possible Culprit For Development Of Schizophrenia
Source: Epilepsy News From Medical News Today [2009.10.21]
Researchers say antiepilectic drug treatments administered when the brain is developing appear to trigger schizophrenia-like behavior in animal models. In humans, having a history of seizures in infancy is a significant risk factor for development of schizophrenia later in life, but it is not known whether the elevated risk is due to seizures themselves, or from side effects antiepileptic drug (AED) treatment.
Scientists Demonstrate Link Between Genetic Defect And Brain Changes In Schizophrenia
Source: Schizophrenia News From Medical News Today [2009.10.17]
For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.
Clinical And Regulatory Aspects Of Trials With Negative Symptoms Of Schizophrenia Discussed At ISCTM Meeting
Source: Schizophrenia News From Medical News Today [2009.10.15]
A half-day workshop on issues in the design of clinical trials to evaluate treatments for negative symptoms of schizophrenia, chaired by Stephen Marder, MD, UCLA Department of Psychiatry and David Daniel, M.D., United BioSource Corporation was held 5 October 2009, as part of the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in San Diego, CA.
Case Western Reserve University Researchers Receive $1.25 Million From National Institutes Of Mental Health To Study Schizophrenia
Source: Schizophrenia News From Medical News Today [2009.10.15]
Case Western Reserve University School of Medicine has received $1.25 million from the National Institutes of Mental Health, part of the National Institutes of Health, to study schizophrenia from an interdisciplinary standpoint. The grant, to be funded over four years, includes three project investigators from three different practice areas.
Fear Of Mentally Ill Is Misplaced: Stranger Homicide By People With Schizophrenia Is Rare And Unpredictable
Source: Schizophrenia News From Medical News Today [2009.10.13]
International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events A study initiated by a team of Sydney researchers published in the leading schizophrenia journal, Schizophrenia Bulletin, shows that homicides of strangers by people diagnosed with schizophrenia are exceptionally rare events.
Schizophrenia Gene Linked With Abnormal Neurogenesis In Adult And Postnatal Brain
Source: Schizophrenia News From Medical News Today [2009.09.24]
Scientists now have a better understanding of a perplexing gene that is associated with susceptibility for a wide spectrum of severely debilitating mental illnesses.
New Antipsychotic Drug Asenapine (Saphris) Helps Prevent Relapse In People With Schizophrenia; Phase III Data Presented At ECNP
Source: Schizophrenia News From Medical News Today [2009.09.18]
Schizophrenia is a difficult condition for patients and their families to manage. Relapse is a frequent occurrence, particularly if patients decide to discontinue antipsychotic drug treatment because of unwanted side effects. Psychiatrists say over half of patients relapse within two years and over 80 per cent within five years. Relapse is five times more likely to occur among patients who stop their treatment.
Schizophrenia: 22nd Congress Of The European College Of Neuropsychopharmacology, Sept. 14, 2009, Istanbul, Turkey
Source: Schizophrenia News From Medical News Today [2009.09.16]
Schizophrenia is a major public health problem. Affecting almost 1% of the world's population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease. Elements of the disease are present from birth, other aspects emerge during developmental years, and the illness becomes fully expressed in early adulthood with long-lasting implications for most patients.
Brain Scans Could Help Spot Schizophrenia Earlier
Source: MedicineNet Schizophrenia Specialty [2009.09.10]
Title: Brain Scans Could Help Spot Schizophrenia Earlier
Category: Health News
Created: 9/9/2009 4:10:00 PM
Last Editorial Review: 9/10/2009
FDA Approves Saphris Tablets (asenapine) To Treat Schizophrenia And Bipolar Disorder
Source: Bipolar News From Medical News Today [2009.08.16]
The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat bipolar I disorder in adults, a serious psychiatric disorder that causes shifts in a person's mood, energy, and ability to function. "Mental illnesses like schizophrenia and bipolar disorder can be devastating to patients and families, requiring lifelong treatment and therapy," said Thomas Laughren, M.D.
Schering-Plough Announces FDA Approval Of SAPHRIS(R) (asenapine) For Acute Treatment Of Schizophrenia In Adults And Manic Or Mixed Episodes Of Bipolar
Source: Bipolar News From Medical News Today [2009.08.15]
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously.
Saphris Approved for Schizophrenia and Bipolar Disorder
Source: MedicineNet Bipolar Disorder Specialty [2009.08.14]
Title: Saphris Approved for Schizophrenia and Bipolar Disorder
Category: Health News
Created: 8/14/2009 10:30:00 AM
Last Editorial Review: 8/14/2009
FDA Advisory Committee Votes In Favor Of SAPHRIS(R) (asenapine) For Acute Bipolar I Disorder And Acute Schizophrenia
Source: Bipolar News From Medical News Today [2009.07.31]
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of use in acute treatment of schizophrenia in adults.
Schizophrenia Drug Got Bad Rap
Source: MedicineNet Schizophrenia Specialty [2009.07.13]
Title: Schizophrenia Drug Got Bad Rap
Category: Health News
Created: 7/13/2009 7:00:00 AM
Last Editorial Review: 7/13/2009
Schizophrenia And Bipolar Disorder Share Genetic Roots
Source: Bipolar News From Medical News Today [2009.07.04]
A trio of genome-wide studies - collectively the largest to date - has pinpointed a vast array of genetic variation that cumulatively may account for at least one third of the genetic risk for schizophrenia. One of the studies traced schizophrenia and bipolar disorder, in part, to the same chromosomal neighborhoods. "These new results recommend a fresh look at our diagnostic categories," said Thomas R. Insel, M.D.
A Combination Of Common Genetic Variations Can Lead To Schizophrenia
Source: Bipolar News From Medical News Today [2009.07.02]
A multi-national group of investigators, including a scientist at the University of North Carolina at Chapel Hill, has discovered that nearly a third of the genetic basis of schizophrenia may be attributed to the cumulative actions of thousands of common genetic variants. The effects of each of these genetic changes, innocuous on its own, add up to a significant risk for developing both schizophrenia and bipolar disorder.
Schizophrenia And Bipolar Disorder Share Many Common Genetic Variants Says International Research Consortium
Source: Bipolar News From Medical News Today [2009.07.02]
A new study by a large international consortium found that many common genetic variants contribute up to a third of a person's risk of inheriting schizophrenia and many of the same DNA variations are also involved in bipolar disorder. While the study helps to explain the complexity of the genetic make up of these diseases it also suggests that developing a test to predict these diseases will take some time.
Possible Gene Regions for Schizophrenia Located
Source: MedicineNet Schizophrenia Specialty [2009.07.02]
Title: Possible Gene Regions for Schizophrenia Located
Category: Health News
Created: 7/2/2009 7:00:00 AM
Last Editorial Review: 7/2/2009
Monthly Shot Treats Schizophrenia
Source: MedicineNet aripiprazole Specialty [2008.05.08]
Title: Monthly Shot Treats Schizophrenia
Category: Health News
Created: 5/8/2008
Last Editorial Review: 5/8/2008
Zyprexa in schizophrenia shown to prevent brain loss
Source: The Doctors Lounge - Psychiatry
Zyprexa (olanzapine) was found to decrease brain loss in schizophrenia patients according to the Archives of General Psychiatry.
Metabolic Effects Significantly Lower With INVEGA(R) Compared To Olanzapine
Source: Health News from Medical News Today [2009.11.19]
New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.1 The results were presented at the 15th Biennial Winter Workshop in Psychoses in Barcelona, Spain.
Heart Disease A 'Silent Killer' In Patients With Severe Mental Illness
Source: Mental Health News From Medical News Today [2009.11.15]
A large new study confirms that people with severe mental disorders - such as schizophrenia or other psychotic disorders - are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are. Moreover, smoking and physical inactivity - behaviors that individuals potentially can change - significantly contribute to this increased risk of death, found researchers led by Amy Kilbourne, Ph.D.
New Findings Of Autism-Associated Synapse Alterations Lead To Coveted NIH Grant For Stanford Scientist
Source: Schizophrenia News From Medical News Today [2009.10.13]
A Stanford University School of Medicine researcher has pinpointed the mechanism by which a gene associated with both autism and schizophrenia influences behavior in mice. And just recently, he received a $1.65 million government grant to expand his efforts to include many more such genes. In a study published online on Oct.
UNC Study Pinpoints Gene Controlling Number Of Brain Cells
Source: Bipolar News From Medical News Today [2009.10.06]
The finding suggests that a single gene, called GSK-3, controls the signals that determine how many neurons actually end up composing the brain. This has important implications for patients with neuropsychiatric illness, as links have recently been drawn between GSK-3 and schizophrenia, depression and bipolar disorder.
Practical Advice For Unraveling The Genetics Of Complex Human Diseases: New Book
Source: Schizophrenia News From Medical News Today [2009.09.15]
Many human diseases - including Alzheimer's disease, schizophrenia, cancer, and cardiovascular disease - are caused by multiple genetic variants and the interaction of those variants with the environment. Because such diseases lack a clear-cut inheritance pattern, sophisticated technological approaches and statistical analyses are required to determine their underlying cause.
FDA Advisory Committee Votes In Favor Of Zyprexa For Two Adolescent Indications
Source: Bipolar News From Medical News Today [2009.06.12]
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.
|
